What question did this study set out to answer?

To evaluate clinical trial and real-world evidence regarding the effects of belimumab on organ damage accumulation and related clinical endpoints in adults with systemic lupus erythematosus.

April 19, 2022Arthritis Care & ResearchOpen Access

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

View Full Paper

Ask AI

Bookmark

Authors

MUMurray B. UrowitzToronto Western Hospital CACynthia AranowNorthwell Health YAYumi AsukaiGilead Sciences (United Kingdom)

Discussion

Member takes

Implication

Review demonstrates reduced organ damage progression with belimumab in systemic lupus erythematosus, highlighting potential disease-modifying effects.

Key Points

To evaluate clinical trial and real-world evidence regarding the effects of belimumab on organ damage accumulation and related clinical endpoints in adults with systemic lupus erythematosus.
Reviewed data from four phase III randomized clinical trials, long-term open-label extension studies, and propensity score-matched comparative cohorts.
Assessed outcomes comparing belimumab added to background therapy versus background therapy alone in adults with active systemic lupus erythematosus and lupus nephritis.
Evaluated key measures including systemic lupus activity, severe flares, glucocorticoid exposure, renal response, and organ damage progression assessed via the SLICC/ACR Damage Index.
Belimumab added to background therapy consistently reduced disease activity, severe flare risk, and glucocorticoid exposure compared to background therapy alone across four phase III trials.
Open-label extension studies and propensity score-matched analyses demonstrated a significant reduction in organ damage progression measured by the SLICC/ACR Damage Index with long-term belimumab use.
In active lupus nephritis, belimumab treatment improved renal response rates, lowered the risk of renal-related events, and attenuated drivers of long-term kidney damage.

Cite This Study

Urowitz et al. (2022) studied this question.

synapsesocial.com/papers/6a1ec09ce5c5a32e9d9a88ce https://doi.org/10.1002/acr.24901

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates reduced organ damage progression with belimumab in systemic lupus erythematosus, highlighting potential disease-modifying effects.

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider